MFAT (microfragmented adipose tissue, from your fat) and BMA (bone marrow aspirate, from your pelvis) are the two autologous stem cell sources. They are alternatives, never combined, and neither is universally better. The right one is a physician decision made for your specific joint, from imaging, your age, body composition, the stage of arthritis, and prior procedures, not whichever source a clinic happens to stock. At Dynamic Athlete, Dr. Aneesh Garg, DO, CAQ selects the source, then co-delivers it with High-Dose PRP and Fibrin-Rich Plasma under live ultrasound, as the Dynamic Stem Cell+ protocol.
If you searched MFAT vs BMA, you want to know which one is right for you. The honest answer is that the choice is the medicine. So judge a clinic on whether a physician makes that choice from your imaging, or sells you the one source it owns.
The Decision
The question is not “which acronym is stronger.” It is “who chooses, and on what evidence.” A source matched to your joint by a physician under imaging is a different product from the one source a clinic stocks and offers to everyone.
Hold any clinic to one standard: both MFAT and BMA available, the source named after your evaluation, and the physician who chooses it performing the procedure. That is what makes your best choice verifiable.
- MFAT is your fat; BMA is your bone marrow. Both are autologous, same-day, minimally manipulated tissue, not donor vials and not drugs.
- They are alternatives, never combined. Neither is universally better; the right source depends on the joint, the stage of arthritis on imaging, your age, and body composition.
- The source should be named after the evaluation, not before. A clinic that stocks one source recommends that source to everyone.
- Whichever is chosen, it is co-delivered with High-Dose PRP (12 to 20 times baseline) and Fibrin-Rich Plasma, placed under live ultrasound by Dr. Garg, not a technician.
- over 90% of patients self-report 75% or greater improvement, all without surgery with Dynamic Stem Cell+. Self-reported, never guaranteed.
- Out-of-pocket; HSA and FSA dollars typically apply, and Cherry financing spreads the cost monthly.
MFAT and BMA, compared
Two sources of your own regenerative tissue, two harvest sites, one decision.
| MFAT | BMA | |
|---|---|---|
| What it is | Microfragmented adipose tissue | Bone marrow aspirate |
| Harvest site | Your own fat (mini-liposuction) | Your own iliac crest (pelvis) |
| Cell profile | Dense structural scaffold from fat | Marrow-derived cell population |
| Often chosen for | A more degenerated joint; fat tolerates the environment well | Cases where a marrow-derived population is the better match |
| Co-delivered with | High-Dose PRP and Fibrin-Rich Plasma | High-Dose PRP and Fibrin-Rich Plasma |
What is the same, and what differs
Both are autologous, same-day, minimally manipulated procedures: your own tissue, not a donor vial or a drug. Whichever is selected, it is co-delivered with High-Dose PRP and Fibrin-Rich Plasma and placed under live ultrasound. What differs is the harvest and the cell profile. MFAT comes from a small volume of fat and gives a dense structural scaffold that tolerates a degenerated joint well, so it is frequently chosen for a more arthritic joint. BMA is drawn from the pelvis and supplies a marrow-derived population. Neither is a default.
Why the choice is the medicine
The variable that decides your result is not which source is fashionable. It is whether a physician matched the source to your joint, and whether it was paired and placed correctly.
The source is selected from your imaging, not from a menu
Dr. Garg weighs the stage of arthritis on your imaging, the joint, your age and body composition, prior procedures, and your goals, then names MFAT or BMA. The evidence supports both for knee osteoarthritis: a 2022 randomized trial in The American Journal of Sports Medicine found bone marrow aspirate concentrate and PRP produced equivalent two-year outcomes. With both supported, the decision belongs to the joint in front of you, not to whichever source a clinic stocks.
Whichever source, it is never injected alone
Neither MFAT nor BMA goes in bare. The selected source is always co-delivered with High-Dose PRP, platelets concentrated 12 to 20 times baseline (over 10 billion), versus the 2 to 3 times most clinics produce, plus Fibrin-Rich Plasma. The platelets and fibrin are the signaling and scaffolding environment around the cells, and the fibrin helps keep the material at the target. Source plus High-Dose PRP is the pairing that matters, not MFAT plus BMA.
The physician who chooses the source also performs it
Stem cell therapy is image-guided medicine, not a commodity injection. The harvest, the preparation, and the placement each carry judgment. Every Dynamic Stem Cell+ procedure is performed by Dr. Aneesh Garg, DO, CAQ, from source selection through live ultrasound delivery, not a technician. He is regenerative-medicine teaching faculty at RMTI and Rocky Vista University, the physician who teaches this work to other physicians.
Print this before you choose a source
Three questions separate a physician-selected source from a single product sold under the stem cell label. Ask all three. Most clinics will fail at least one.
- Do you offer both MFAT and BMA, and does a physician select the source for my joint? A clinic that stocks one source recommends that source to everyone.
- Is this my own tissue, MFAT or BMA, rather than a donor vial? An amniotic or umbilical cord product is a different category that may not contain living cells.
- Who performs it, and is it placed under live ultrasound? “The physician, under live ultrasound” and “High-Dose PRP at 12 to 20 times baseline” are the answers you want.